Melanoma Drug Effective in Trials

Monday, 18 Nov 2013 04:57 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Early data from a small trial of Merck & Co Inc's experimental immunotherapy cancer drug, known as MK-3475, show that about half of advanced melanoma patients treated with the highest dose of the drug experienced tumor shrinkage.

Updated results from the early-stage trial are set to be presented on Monday at the International Congress of the Society for Melanoma Research in Philadelphia.

The antibody drug is part of a new class of compounds designed to block the activity of a receptor on immune cells called programmed death 1, or PD-1. The aim of the drugs is to spur the body's own immune system to attack cancer cells.

Merck said results from 135 patients whose melanoma had stopped responding to earlier rounds of treatment showed that 41 percent had tumor shrinkage - the rate was 51 percent in the high-dose group, and 40 percent for lowest-dose group.

The company estimated overall survival at a year of treatment at 81 percent, but said the trial had not yet reached either a median duration of response or median overall survival.

Serious side effects seen in the trial included fatigue, rash, increased liver enzymes and renal
failure.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Blood Sugar Control Doesn't Help Diabetics Avoid Heart Attacks: Study

Saturday, 20 Sep 2014 09:06 AM

A six-year study of people with type 2 diabetes found that intensively lowering blood pressure had a long-lasting effect . . .

700 Babies Possibly Exposed to TB at Texas Hospital

Friday, 19 Sep 2014 23:45 PM

More than 700 infants may have been exposed to tuberculosis at an El Paso hospital over the past year by an employee rec . . .

Did FDA Food-Dragging Delay New Diet Pill Approval?

Friday, 19 Sep 2014 17:24 PM

The FDA's approval of the new diet pill Contrave could have come more than three years ago, an agency critic argues. . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved